HF-0299(HF-0299) - 药物靶点：IGF-1_在研适应症：神经痛_专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点

IGF-1

作用机制

IGF-1刺激剂(胰岛素样生长因子-I刺激剂)

治疗领域

神经系统疾病

在研适应症

神经痛

非在研适应症

痛经

原研机构

Deutsches Zentrum für Luft- und Raumfahrt e.V.

在研机构

Newron Pharmaceuticals SpA

Deutsches Zentrum für Luft- und Raumfahrt e.V.

非在研机构

Nobelpharma Co., Ltd.

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C19H26O3

InChIKeyWSCUHXPGYUMQEX-KCZNZURUSA-N

CAS号382-44-5

关联

2

项与 HF-0299 相关的临床试验

JPRN-JapicCTI-101118 / Unknown status临床3期

Phase3,Randomized,Double-Blinded,Clinical Trial of NPC-01 for Treatment of Dysmenorrhea.

开始日期-

申办/合作机构

Nobelpharma Co., Ltd.

JPRN-jRCT2080221084 / Unknown status临床3期

Phase3,Randomized,Double-Blinded,Clinical Trial of NPC-01 for Treatment of Dysmenorrhea.

开始日期2010-04-30

申办/合作机构

Nobelpharma Co., Ltd.

100 项与 HF-0299 相关的临床结果

登录后查看更多信息

100 项与 HF-0299 相关的转化医学

登录后查看更多信息

100 项与 HF-0299 相关的专利（医药）

登录后查看更多信息

4

项与 HF-0299 相关的文献（医药）

2018-01-01·Evidence-Based Complementary and Alternative Medicine4区 · 医学

Traditional Herbal Formula NPC01 Exerts Antiangiogenic Effects through Inhibiting the PI3K/Akt/mTOR Signaling Pathway in Nasopharyngeal Carcinoma Cells

4区 · 医学

ArticleOA

作者: Pan, Zhanyu ; Yinli, Yang ; Yanwei, Li

Antiangiogenic therapy is vital in nasopharyngeal carcinoma (NPC) treatment. NPC01 has already been successfully used in treating patients with NPC in clinical practice and exerted an excellent antiangiogenetic effect. However, the potential molecular mechanism underlying the antitumor effect of NPC01 has not been well explored. The present study demonstrated that NPC01 could significantly inhibit cell proliferation and induce cell apoptosis in a dose‐dependent manner in human NPC cell lines. Furthermore, NPC01 exerted antiproliferative and antiangiogenic effects in NPC xenograft mice. Moreover, the study showed that NPC01 could significantly decrease the expression of angiogenesis‐associated factors including hypoxia‐inducible factor‐1α and vascular endothelial growth factor. Additionally, the decreased expression of these angiogenesis‐associated factors could be due to the inhibition of the phosphoinositide 3‐kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) signaling pathway (PI3K/Akt/mTOR). In conclusion, the results proposed that NPC01 could exert its antitumor effect by suppressing the PI3K/Akt/mTOR signaling pathway. Further studies are warranted to elucidate the molecular mechanism.

2016-12-01·Fertility and Sterility2区 · 医学

Evaluation of an ultra-low-dose oral contraceptive for dysmenorrhea: a placebo-controlled, double-blind, randomized trial

2区 · 医学

Article

作者: Momoeda, Mikio ; Harada, Tasuku

OBJECTIVETo evaluate the efficacy and safety of an ultra-low-dose oral contraceptive (NPC-01; 0.02 mg ethinyl estradiol and 1 mg norethisterone) in subjects with dysmenorrhea.DESIGNPlacebo-controlled, double-blind, randomized trial.SETTINGClinical trial sites.PATIENT(S)Two hundred fifteen subjects with dysmenorrhea.INTERVENTION(S)Subjects were randomly assigned to receive NPC-01, placebo, or IKH-01 (0.035 mg ethinyl estradiol and 1 mg norethisterone) for four cycles.MAIN OUTCOME MEASURE(S)Total dysmenorrhea score (verbal rating scale) assessing pain on the basis of limited ability to work and need for analgesics.RESULT(S)The reductions of total dysmenorrhea score and visual analog scale score after the treatment were significantly higher in the NPC-01 group than in the placebo group. Furthermore, the efficacy of NPC-01 was comparable to that of IKH-01. The overall incidence of side effects was significantly higher in the NPC-01 group than in the placebo group. All side effects that occurred in the NPC-01 group were previously reported in patients receiving IKH-01. No serious side effects occurred.CONCLUSION(S)The ultra-low-dose contraceptive NPC-01 relieved dysmenorrhea as effectively as IKH-01. Thus, NPC-01 could represent a new option for long-term treatment of dysmenorrhea.CLINICAL TRIAL IDENTIFICATION NUMBERNCT01129102.

2012-01-01·Current Drug Delivery4区 · 医学

The Use of Specific Monoclonal Antibodies to Target Immunogenic Tumor Membrane Proteins in Patients with Recurrent Pancreatic and Colon Cancer

4区 · 医学

Article

作者: Gupta, Rishab ; Luka, Janos ; Arlen, Philip M. ; Wang, Xue Ping ; Arlen, Myron ; Saric, Olga

Tumor associated antigens from pooled allogeneic membrane proteins were isolated, partially purified and tested as a possible vaccine in patients with stage II and III colon cancer. The vaccine, when given in combination with an adjuvant following surgical resection, resulted in marked improvement in survival compared to control patients having only undergone surgical resection of their tumor. While it was possible to demonstrate that patients receiving vaccine turned on both humoral and cell mediated responses, it appears that survivors remaining free of disease at 5-7 yrs post op were able to mount a strong IgG1 response as the primary mechanism for tumor destruction. Antibodies from hybridomas made against the vaccines resulted in production of monoclonals with a high degree of ADCC. Those monoclonals targeting pancreatic cancer and in particular the MUC5ac mutated antigen representing tumor immunogen were studied in detail. Animal models indicated rapid tumor destruction when nude mice, injected with human pancreatic cancer were then immunized with NPC-1 monoclonal antibody targeting mutated MUC5ac. FDA studies including tissue cross reactivity, biodistribution, and cytokine release assays indicated safety and efficacy of the monoclonals we have developed. Submission of the IND allowed for initiation of the Phase I trial using mAb NPC-1 targeting pancreatic cancer when that antigen was found to be expressed.

100 项与 HF-0299 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
神经痛	临床1期	-	Deutsches Zentrum für Luft- und Raumfahrt e.V.	-
神经痛	临床1期	-	Newron Pharmaceuticals SpA	-
痛经	药物发现	-	Nobelpharma Co., Ltd.	2009-05-01